Intellectual Property

Primary Peptides has filed or obtained patents on its core technologies, and has also developed considerable “knowhow” and trade secrets around these technologies.  In addition, Primary Peptides scientists have either filed or obtained patents for lead compound therapeutics in the areas of Stroke, Neurotrauma, Neurodegenerative Disorders (including Alzheimer’s, Parkinson’s, Frontotemporal Dementia, and ALS), as well as other indications.

Patent filings for other indications are currently in preparation.